HTGC — Hercules Capital, Inc. Stock Price, Chart & AI Report

Neutral Nov 5, 2025 • 12:00 UTC GlobeNewswire Inc. • Moonlake Immunotherapeutics

MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab

MoonLake Immunotherapeutics reported Q3 2025 financial results, highlighting positive clinical trial data for its Nanobody® sonelokimab in treating inflammatory diseases like hidradenitis suppurativa, psoriatic arthritis, and palmoplantar pustulosis. The company ended the quarter with $380.5 million in cash and expects funding into the second half of 2027.

MLTX HCXY HTGC sonelokimab nanobody clinical trials inflammatory diseases hidradenitis suppurativa

Sentiment note

Mentioned as a debt facility provider with no specific performance details

Negative Oct 12, 2025 • 22:20 UTC The Motley Fool • Jake Lerch

Investment Manager Rebalances, Trims Stake in Hercules Capital

Sound Income Strategies sold 177,473 shares of Hercules Capital for approximately $3.40 million in Q3 2025, reducing its stake while maintaining over 2.7 million shares. Hercules Capital has underperformed the S&P 500 over the past year.

HCXY HTGC venture debt investment stock sale financial services

Sentiment note

Stock has fallen 15% in the last month, posted a negative total return of (6.2%), and underperformed the S&P 500 by 23.78 percentage points over the past year

Neutral Jul 14, 2025 • 21:00 UTC GlobeNewswire Inc. • Guillermo Novo

Operations leadership changes announced at Ashland

Ashland Inc. announced Karl Bostaph's retirement as senior vice president of operations, with Wayne Muil taking over the role effective immediately. Muil brings over 25 years of global operations experience and will oversee Ashland's production facilities worldwide.

HCXY HTGC ASH leadership transition operations retirement manufacturing executive change

Sentiment note

Mentioned as a historical context for Karl Bostaph's career prior to Ashland's acquisition

Positive Apr 3, 2025 • 11:00 UTC GlobeNewswire Inc. • N/A

MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates

MoonLake Immunotherapeutics secures up to $500 million in non-dilutive financing from Hercules Capital, strengthening its financial position to advance its lead candidate sonelokimab. The company plans to provide clinical updates, including on its Phase 3 trials in hidradenitis suppurativa and Phase 2 trial in palmoplantar pustulosis.

MLTX HCXY HTGC MoonLake Immunotherapeutics Hercules Capital sonelokimab hidradenitis suppurativa palmoplantar pustulosis

Sentiment note

Hercules Capital is described as a leader in customized debt financing for life sciences companies, and the article emphasizes the company's recognition of the value and potential of sonelokimab, as well as its commitment to empowering biotech companies.

Positive Dec 31, 2024 • 09:17 UTC The Motley Fool • The Motley Fool

Want $500 of Reliable Dividend Income in 2025? Invest $5,040 in These 3 Ultra-High-Yield Stocks.

The article recommends investing in three business development companies (BDCs) - Ares Capital, PennantPark Floating Rate Capital, and Hercules Capital - to generate $500 in annual dividend income by 2025 with an initial investment of $5,040. The BDCs offer high dividend yields ranging from 8.7% to 11.3%.

ARCC PFLT HCXY HTGC dividend income business development companies high-yield stocks

Sentiment note

The article highlights Hercules Capital's unique approach of investing in innovative technology and life science companies, which can provide significant upside potential, and its reliable quarterly dividend distribution.

Positive Oct 20, 2024 • 10:24 UTC The Motley Fool • Cory Renauer

3 Dividend Growth Stocks to Buy Now for a Lifetime of Passive Income

The article discusses three companies - Archer-Daniels-Midland, Hercules Capital, and Royalty Pharma - that are rapidly growing their dividend payouts, making them attractive long-term investments for building a passive income stream for retirement.

ADM HCXY HTGC RPRX dividend investing retirement planning Archer-Daniels-Midland Hercules Capital

Sentiment note

The article praises Hercules Capital's ability to generate a high dividend yield, both through its regular quarterly dividend and supplemental dividends, despite the inherent risks of investing in start-up businesses in the life sciences and technology industries.

Positive Oct 12, 2024 • 09:26 UTC The Motley Fool • The Motley Fool

3 Reliable Dividend Stocks With Yields Above 5% That You Can Buy With Less Than $100 Right Now

The article highlights three dividend-paying stocks - AT&T, Hercules Capital, and Pfizer - that offer yields above 5% and can be purchased for less than $100. It discusses the growth drivers and reliable dividend payouts of these companies.

T TBB TBC TPA dividend stocks high yield AT&T Hercules Capital

Sentiment note

The article notes Hercules Capital's approach of financing start-ups in the life science and technology industries, which has allowed the company to report strong earnings growth and maintain its dividend payout.

Positive Sep 10, 2024 • 00:55 UTC The Motley Fool • The Motley Fool

1 Ultra-High-Yield Dividend Stock You'll Want to Have on Your Radar as Rate Cuts Loom

The article discusses Hercules Capital (HTGC), a business development company (BDC) that could benefit from potential interest rate cuts. Hercules focuses on lending to early-stage technology, life sciences, and green energy companies, and has consistently increased its net investment income and dividend payments over the years.

HCXY HTGC SPY Hercules Capital BDC interest rates dividend technology

Sentiment note

The article highlights Hercules Capital as a well-positioned BDC that could benefit from potential interest rate cuts. It has consistently increased its net investment income and dividend payments, and offers flexible financing solutions to venture-backed companies, which could see increased demand for its services if rates decline.

Positive Aug 23, 2024 • 07:23 UTC The Motley Fool • Adam Spatacco

Here Are My Top 5 Dividend Stocks to Buy in August

The article explores five dividend stocks that could be attractive investments during the current market volatility, including Hercules Capital, Ares Capital, AT&T, Verizon, and Altria.

HCXY HTGC ARCC T dividend stocks market volatility passive income

Sentiment note

The article highlights Hercules Capital's strong performance, with a 10.4% dividend yield and a well-managed portfolio, making it an attractive investment opportunity.

Neutral Aug 2, 2024 • 11:56 UTC Zacks Investment Research • N/A

Hercules Capital (HTGC) Q2 Earnings Meet Estimates, Costs Up

Hercules Capital Inc.'s Q2 2024 net investment income matched estimates, but declined year-over-year due to higher operating expenses. The company's total investment income and portfolio value remained strong, but expenses rose due to increased interest and compensation costs.

HCXY HTGC ARCC TREE Hercules Capital investment income expenses portfolio value

Sentiment note

The article presents a mixed outlook for Hercules Capital, with the company's investment income and portfolio value remaining strong, but expenses also rising, leading to a decline in net investment income year-over-year. The overall sentiment is neutral as the company's performance is a mix of positive and negative factors.

Positive Jul 22, 2024 • 08:07 UTC The Motley Fool • Adam Spatacco

Bull Market Buys: 2 Tantalizing Ultra-High-Yield Dividend Stocks to Buy Hand Over Fist Right Now - The Motley Fool

The article discusses two business development companies (BDCs) - Hercules Technology Growth Capital and Ares Capital - that offer high dividend yields of around 9%. Both companies are seen as attractive investment opportunities for passive income investors.

HCXY HTGC ARCC business development companies dividend stocks high-yield Hercules Technology Growth Capital Ares Capital

Sentiment note

The article highlights Hercules' ability to generate steady income from its loan portfolio and potential upside from warrants, despite the risk of inconsistent cash flow from its borrowers. The company's low non-accrual rate is seen as a positive.

Neutral Jul 16, 2024 • 21:54 UTC Investing.com • Lina Guerrero

Eloxx Pharmaceuticals secures $3.2 million in additional funding - Investing.com

Eloxx Pharmaceuticals, a biopharmaceutical company, has secured an additional $3.175 million in funding through a loan agreement amendment with Hercules Capital and other lenders. The funding will be used for the company's operations and development of its ELX-02 compound.

ELOX HCXY HTGC Eloxx Pharmaceuticals Hercules Capital funding loan agreement ELX-02

Sentiment note

The article mentions Hercules Capital as a lender to Eloxx Pharmaceuticals, but does not provide any additional information about the company, so a neutral sentiment is assigned.